Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Pancreatic cancer is almost invariably associated with mutations in the KRAS gene, most commonly KRASG12D, that result in a dominant-active form of the KRAS GTPase. However, how KRAS mutations promote pancreatic carcinogenesis is not fully understood, and whether oncogenic KRAS is required for the maintenance of pancreatic cancer has not been established. To address these questions, we generated two mouse models of pancreatic tumorigenesis: mice transgenic for inducible KrasG12D, which allows for inducible, pancreas-specific, and reversible expression of the oncogenic KrasG12D, with or without inactivation of one allele of the tumor suppressor gene p53. Here, we report that, early in tumorigenesis, induction of oncogenic KrasG12D reversibly altered normal epithelial differentiation following tissue damage, leading to precancerous lesions. Inactivation of KrasG12D in established precursor lesions and during progression to cancer led to regression of the lesions, indicating that KrasG12D was required for tumor cell survival. Strikingly, during all stages of carcinogenesis, KrasG12D upregulated Hedgehog signaling, inflammatory pathways, and several pathways known to mediate paracrine interactions between epithelial cells and their surrounding microenvironment, thus promoting formation and maintenance of the fibroinflammatory stroma that plays a pivotal role in pancreatic cancer. Our data establish that epithelial KrasG12D influences multiple cell types to drive pancreatic tumorigenesis and is essential for tumor maintenance. They also strongly support the notion that inhibiting KrasG12D, or its downstream effectors, could provide a new approach for the treatment of pancreatic cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [7]
In the citing paper
“Extinguishing the expression of mutant Kras in the pancreas led to rapid tumor regression, thus demonstrating a critical role of Kras in tumor maintenance (73, 78).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [78]
In the citing paper
“Withdrawal of oncogenic Kras resulted in regression of invasive neoplasia, including regression of metastatic disease63–65.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [63]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Tumor spectrum analysis in p53-mutant mice
Jacks, T., Remington, L., Williams, B. O., Schmitt, E. M., Halachmi, S., Bronson, R. T., & Weinberg, R. A. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00002-6 · Cited by 2,051
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Addiction to Oncogenes--the Achilles Heal of Cancer
Weinstein, I. B. (2002) · Science · doi:10.1126/science.1073096 · Cited by 1,728
Research works printed but not linked: 2
- Klimstra, 1994, Am J Pathol., 145, 1547
- Caldwell, Oncogene.
Cited by
Items 501–600 of 769
Palanivel, C., Chaudhary, N., Seshacharyulu, P., Cox, J. L., Yan, Y., Batra, S. K., & Ouellette, M. M. (2022) · Neoplasia · doi:10.1016/j.neo.2022.01.002 · Cited by 13
Targeting KRAS Inhibitor–Resistant Pancreatic Cancer with an MUC1-C Antibody–Drug Conjugate
Ozawa, H., Takahashi, K., Motegi, T., Jacobi, J. J., Bhattacharya, A., Shigeta, K., Takamori, S., Onishi, M., Luan, Z., Fukuda, K., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2333 · Cited by 14
“More than 40% of PDAC tumors harbor the KRAS G12D mutation (9–11).”
Reyes, J., Priore, I. S. D., Chaikovsky, A. C., Pasnuri, N., Elhossiny, A. M., Park, J., Weiler, P., Krause, T., Moorman, A. R., Snopkowski, C., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.032 · Cited by 21
Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
Barravecchia, I., Lee, J. M., Manassa, J., Magnuson, B., Ferris, S. F., Cavanaugh, S., Steele, N. G., Espinoza, C. E., Galbán, C. J., Ramnath, N., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0480 · Cited by 13
Self-citationMeng, F., Li, T., Singh, A. K., Wang, Y., Attiyeh, M. A., Kohram, F., Feng, Q., Li, Y. R., Shen, B., Williams, T. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114820 · Cited by 15
Urrutia, G., de Assuncao, T. M., Mathison, A., Salmonson, A., Kerketta, R., Zeighami, A., Stodola, T. J., Adsay, V. N., Pehlivanoğlu, B., Dwinell, M. B., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.681153 · Cited by 12
Hara, Y., Mizukami, H., Yamazaki, K., Yamada, T., Igawa, A., Takeuchi, Y., Sasaki, T., Kushibiki, H., Murakami, K., Kudoh, K., et al. (2023) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.326 · Cited by 12
Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality
Donahue, T. R., & Dawson, D. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.009 · Cited by 13
“KRAS-Dependency in PDA Elegant studies utilizing PDA GEMMs that reversibly induce oncogenic Kras expression demonstrate that it is essential for the development and maintenance of all stages of PanIN and PDA, acting to regulate pro-tumorigenic inflammatory and stromal signaling [30] and to reprogram cellular metabolis…”
BackgroundMurine Models of Pancreatitis Leading to the Development of Pancreatic Cancer
Leal, A. S., & Liby, K. T. (2018) · Current Protocols in Pharmacology · doi:10.1002/cpph.48 · Cited by 12
Mottini, C., & Cardone, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145023 · Cited by 13
Zhu, L., Ji, J., Ma, J., Wang, D., Liu, M., Du, J. X., Chen, R., Hou, W., Abbruzzese, J. L., Logsdon, C. D., et al. (2022) · Cancers · doi:10.3390/cancers14112723 · Cited by 12
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
Akhuba, L. G., Tigai, Z. G., & Shek, D. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2022.142 · Cited by 13
Aggrey-Fynn, J. E., Manjunath, M., Rajput, A., Abdelrahman, A. M., Thiel, J., Truty, M. J., Clark, A. G., Dong, M., & Johnsen, S. A. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07810-x · Cited by 14
“PDAC is associated with various genetic mutations and alterations, with Kirsten rat sarcoma virus ( KRAS ) mutations in over 90% of cases [5].”
Utilizing Salmonella to treat solid malignancies
Ebelt, N. D., & Manuel, E. R. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24644 · Cited by 9
Grant, T. J., Mehta, A. K., Gupta, A., Sharif, A. A. D., Arora, K. S., Deshpande, V., Ting, D. T., Bardeesy, N. M., Ganem, N. J., Hergovich, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20833 · Cited by 10
“Indeed, KRAS plays a critical role in PDAC initiation and maintenance, making it an attractive therapeutic target [7].”
BackgroundExpression profiles analysis of pancreatic cancer.
Yang, D., Zhu, Z., Wang, W., Shen, P., Wei, Z., Wang, C., & Cai, Q. (2013) · PubMed · Cited by 10
Baer, J. M., Zuo, C., Kang, L., de la Lastra, A. A., Borcherding, N. C., Knolhoff, B. L., Bogner, S. J., Zhu, Y., Lewis, M. A., Zhang, N., et al. (2022) · SSRN Electronic Journal · doi:10.1101/2022.02.09.479745 · Cited by 10
“Previous studies have shown that brief cerulein administration accelerates transformation and tumor growth (Collins et al., 2012; Guerra et al., 2007).”
BackgroundMahadevan, K. K., McAndrews, K. M., LeBleu, V. S., Yang, S., Lyu, H., Li, B., Sockwell, A. M., Kirtley, M. L., Morse, S. J., Diaz, B. A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528757 · Cited by 10
“Genetically engineered mouse models revealed that KrasG12D is critical for the initiation and maintenance of PDAC (Collins et al., 2012; Hingorani et al., 2003; Hingorani et al., 2005; Ying et al., 2012), suggesting that mutant Kras is a viable therapeutic target for the control of PDAC progression.”
BackgroundTumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaPreprint
Wasko, U. N., Jiang, J., Curiel‐García, Á., Wang, Y., Lee, B. J., Orlen, M., Drizyte‐Miller, K., Menard, M. J., Dilly, J., Sastra, S. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.03.569791 · Cited by 10
“Studies of Kras G12D gene deletion in engineered mouse models demonstrate that mutant KRAS plays an essential role in the maintenance of PDAC 17-19 .”
BackgroundEctopic expression of DOCK8 regulates lysosome-mediated pancreatic tumor cell invasion
Gutierrez-Ruiz, O. L., Johnson, K. M., Krueger, E. W., Nooren, R. E., Cruz-Reyes, N., Heppelmann, C. J. H., Hogenson, T. L., Fernández-Zapico, M. E., McNiven, M. A., & Razidlo, G. L. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113042 · Cited by 12
“13,32 The lysosomal transmembrane protein TMEM192–3xHA was stably expressed in iKRAS cells to label lysosomes (Figures S1A and S1B), and lysosomes were isolated by immunoprecipitation using anti-HA magnetic beads 33 from cells treated with or without doxycycline, thus expressing KRAS G12D or KRAS…”
An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 11
“Notably, pathways such as PI3K-Akt and Ras exhibited potential associations with the secretion of inflammatory factors[39, 40].”
BackgroundTinsley, S. L., Chianis, E. R. D., Shelley, R. A., Mall, G. K., Dhiman, A., Baral, G., Kothandaraman, H., Thoma, M. C., English, I. A., Daniel, C. J., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03196-w · Cited by 11
“Quantitative PCR is performed on the QuantStudio 3 using SYBR Green (Fisher Scienti fi c, A25743), and the primers listed on the table below made custom from Integrated DNA Technologies.”
InfluentialRecent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma
Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 14
“Interestingly, upon KRAS inactivation in PDAC that is KRAS G12D -driven, rapid regression of primary and metastatic tumor growth can be observed in the presence of Tp53 deficiency [19,45].”
Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation
Opsahl, E. L. L., Espinoza, C. E., Olivei, A. C., Okoye, J. O., Watkoske, H. R., Hoffman, M. T., Avritt, F. R., Elhossiny, A. M., Bischoff, A. C., Donahue, K. L., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-3472 · Cited by 12
Self-citationAberrant transcription factors in the cancers of the pancreas
Uddin, M. H., Al-Hallak, M. N., Philip, P. A., Chen, H., El‐Rayes, B. F., & Azmi, A. S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.011 · Cited by 11
Murakami, S., White, S. M., McIntosh, A. T., Nguyen, C. D. K., & Yi, C. (2023) · Nature Communications · doi:10.1038/s41467-023-37147-y · Cited by 9
Liou, G., Byrd, C. J., Störz, P., & Messex, J. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094726 · Cited by 10
“Furthermore, evidence from transgenic mouse studies demonstrated that oncogenic Kras G12D mutation is a necessity during PDAC initiation [23,42,43], progression and dissemination [44–46].”
BackgroundCellular collusion: cracking the code of immunosuppression and chemo resistance in PDAC
Musiu, C., Lupo, F., Agostini, A., Lionetto, G., Bevere, M., Paiella, S., Carbone, C., Corbo, V., Ugel, S., & Sanctis, F. D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341079 · Cited by 10
Using microRNAs Networks to Understand Pancreatic Cancer—A Literature Review
Przybyszewski, O., Mik, M., Nowicki, M. P., Kusiński, M., Mikołajczyk-Solińska, M., & Śliwińska, A. (2024) · Biomedicines · doi:10.3390/biomedicines12081713 · Cited by 9
Select Biomarkers for Tumors of the Gastrointestinal Tract: Present and Future
Bartley, A. N., & Hamilton, S. R. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0189-ra · Cited by 9
“KRAS mutations found in precursor pancreatic adenocarcinoma (pancreatic intraepithelial neoplasia) have led to their use as a potential biomarker of the disease.(136) However, KRAS mutations are far from exclusive to malignancy and have been found in chronic pancreatitis and nonmalignant lesions.”
BackgroundAdvanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy
Chiu, J. W. Y., Wong, H., Leung, R. C.-Y., Pang, R. W. C., Cheung, T. T., Fan, S.-T., Poon, R. T. P., & Yau, T. C. C. (2014) · The Oncologist · doi:10.1634/theoncologist.2012-0131 · Cited by 9
Nagawkar, S. S., Abu-Funni, S., Simon, E., Bick, T., Prinz, E., Sabo, E., Ben‐Izhak, O., & Hershkovitz, D. (2015) · Pancreas · doi:10.1097/mpa.0000000000000562 · Cited by 9
Korhan, P., Verkerk, R. M., & Critchley, W. R. (2017) · Integrative Molecular Medicine · doi:10.15761/imm.1000310 · Cited by 9
“KRAS-driven mouse studies showed that oncogenic KRAS (KRASG12D or KRAS G12V) is essential for initiation, progression and maintenance of PDAC and of metastatic lesions [23,24].”
BackgroundA T cell redirection platform for co-targeting dual antigens on solid tumors
Enderle, L., Shalaby, K. H., Gorelik, M., Weiss, A., Blazer, L. L., Paduch, M., Cardarelli, L., Kossiakoff, A. A., Adams, J., & Sidhu, S. S. (2021) · mAbs · doi:10.1080/19420862.2021.1933690 · Cited by 9
“28 KRAS oncogenic transformation induces changes in the composition of the native cell-surface proteins, or “surfaceome,” which facilitates the growth and metastasis of tumors.”
BackgroundElevated DNA damage response in pancreatic cancer
Osterman, M. D., Kathawa, D., Liu, D., Guo, H., Zhang, C., Li, M., Yu, X., & Li, F. (2014) · Histochemistry and Cell Biology · doi:10.1007/s00418-014-1245-7 · Cited by 12
“Immunofluorescence was performed as described previously (Collins et al. 2012).”
MethodSenescence Inflames the Pancreatic Tumor Microenvironment
Petroni, G., & Galluzzi, L. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100020 · Cited by 9
“Genetic alterations common in human PDACs, including activating mutations of KRAS proto-oncogene, GTPase (KRAS), and loss-of-functions mutations in tumor protein p53 (TP53), have beenmechanistically linked to pancreatic oncogenesis amidst an intricate paracrine network that co-opt pancreatic stellate cells (PSCs) to d…”
BackgroundWolfe, A. R., Feng, H., Zuniga, O., Rodrigues, H., Eldridge, D. E., Yang, L., Shen, C., & Williams, T. M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2024.216873 · Cited by 9
Yang, D., Sun, X., Moniruzzaman, R., Wang, H., Citu, C., Zhao, Z., Wistuba, I. I., Wang, H., Maitra, A., & Chen, Y. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101711 · Cited by 11
Salvador-Barberó, B., Alatsatianos, M., Morton, J. P., Sansom, O. J., & Hogan, C. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.042 · Cited by 10
“12 Missense mutations in TP53 are the second most common mutation detected in approximately 70% of human pancreatic ductal adenocarcinoma 13 and required for metastasis.”
Hibshman, P. S., Stalnecker, C. A., Klomp, J. A., Drizyte‐Miller, K., Klomp, J. E., Edwards, A. C., Pita, L. M., Hodge, R. G., Diehl, J. N., Mouery, R. D., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adu7145 · Cited by 10
Park, M. N., Kim, H. S., Park, S., Syahputra, R. A., Delfino, D. V., Ko, S., & Kim, B. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104111 · Cited by 9
“In KRAS-mutant PDAC, both canonical and non-canonical NRF2 activation — mediated by p62 accumulation, GSK3 β inhibition, and β -TrCP interference — sustain SLC7A11 – GSH – GPX4 – dependent ferroptosis defense even under pharmacologic KRAS suppression [8 – 10].”
Pinho, D. F., & Subramaniam, R. M. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.05.003 · Cited by 9
Lee, T., Kim, K., Lee, J., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Park, J. O., & Kim, S. T. (2018) · Journal of Cancer · doi:10.7150/jca.26068 · Cited by 9
“[2-5] KRAS mutation has been known as crucial marker for PDC growth and maintenance and targeting the KRAS is inevitable component for realizing precision medicine to PDA.”
BackgroundClinical significance of pancreatic ductal metaplasia
Jiang, T., Fang, W., & Xie, K. (2022) · The Journal of Pathology · doi:10.1002/path.5883 · Cited by 8
“Coexpression of ductal and acinar markers is usually used to locate PDM lesions; for example, coexpression of digestive enzymes that have not been completely lost, together with ductal markers that have been upregulated [35,62,101,107].”
BackgroundChen, Y., Wang, J., Guo, Q., Li, X., & Zou, X. (2022) · Cancers · doi:10.3390/cancers14215439 · Cited by 7
“Studies have shown that downstream malignant transformation by activated KRAS can promote the development of an immunosuppressive environment in pancreatic cancer, and silencing KRAS can reverse this altered immune microenvironment [32].”
BackgroundResultPan, S., Zhao, W., Li, Y., Ying, Z., Luo, Y., Wang, Q., Li, X., Lu, W., Dong, X., Wu, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1189161 · Cited by 10
“Tumor-cell-intrinsic KRAS mutations could orchestrate a network of immune suppression in tumor microenvironment (TME) (9).”
BackgroundInfluentialNakasone, S., Mimaki, S., Ichikawa, T., Aokage, K., Miyoshi, T., Sugano, M., Kojima, M., Fujii, S., Kuwata, T., Ochiai, A., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2619-3 · Cited by 8
“reported that in a murine model of pancreatic ductal adenocarcinoma, oncogenic KRAS in cancer cells mediates the interaction between cancer cells and stromal cells by activating Hedgehog signaling and inflammatory signaling, which maintain a tumor-promoting microenvironment (Collins et al. 2012).”
BackgroundUncovering key targets of success for immunotherapy in pancreatic cancer
Pretta, A., Lai, E., Persano, M., Donisi, C., Pinna, G., Cimbro, E., Parrino, A., Spanu, D., Mariani, S., Liscia, N., et al. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2010044 · Cited by 8
Inflammatory and immune effects on tumor progression
Mehla, K., & Hollingsworth, M. A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.11.009 · Cited by 9
Enhanced CNN Model for Pancreatic Ductal Adenocarcinoma Classification Based on Proteomic Data
Laxminarayanamma, K., Krishnaiah, R. V., & Sammulal, P. (2022) · Ingénierie des systèmes d information · doi:10.18280/isi.270115 · Cited by 10
“Patients with pancreatic cancer eligible for a possibly healing resection account for just 20% of all patients [6].”
BackgroundWei, R., Zhang, H., Cao, J., Qin, D., Deng, W., & Li, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.839893 · Cited by 8
“There is growing evidence that mutant KRAS drives the establishment of the immunosuppressive microenvironment in PDAC (Collins et al., 2012).”
BackgroundAroclor 1254 causes atrophy of exocrine pancreas in mice and the mechanism involved
Lin, M., Wu, T., Sun, L., Lin, J. J., Zuo, Z., & Wang, C. (2014) · Environmental Toxicology · doi:10.1002/tox.22079 · Cited by 8
Slug inhibits pancreatic cancer initiation by blocking Kras-induced acinar-ductal metaplasia
Ebine, K., Chow, C. R., DeCant, B. T., Hattaway, H. Z., Grippo, P. J., Kumar, K., & Munshi, H. G. (2016) · Scientific Reports · doi:10.1038/srep29133 · Cited by 9
Ras-dependent activation of BMAL2 regulates hypoxic metabolism in pancreatic cancerPreprint
Curiel-Garcia, A., Holmstrom, S. R., Castillo, C., Palermo, C. F., Sastra, S. A., Andren, A. C., Tomassoni, L., Zhang, L., Large, T. Y. S. L., Sagalovskiy, I. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.19.533333 · Cited by 9
“The KRAS oncogene plays a central role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention [62–66].”
Multidimensional analyses identify genes of high priority for pancreatic cancer research
Nwosu, Z. C., Giza, H. M., Nassif, M., Charlestin, V., Menjivar, R. E., Kim, D.-H., Kemp, S. B., Sajjakulnukit, P., Andren, A. C., Zhang, L., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174264 · Cited by 11
“Oncogenic mutations, notably in the KRAS gene, dictate drug sensitivity and drive tumor initiation and progression (6, 7).”
CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer
Lim, S.-A., Todd, H., Goodhart, G., Chang, W.-H., Amparo, A. M., Bridgens, R., Dilly, J., Park, S. J., Beal, R. M., Shehadeh, S. M., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1835 · Cited by 12
“MS1 data were collected over an m/z range of 375–2000 on the Orbitrap [60,000 resolution; automatic gain control (AGC), 4 � 10 5 ].”
Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma
Than, M. T., Dequiedt, L., Sor, R., Nair, S., Markosyan, N., Furth, E. E., Yang, C., Ray-Fofana, C., Menard, M. J., Quintana, E., et al. (2026) · Science · doi:10.1126/science.aec7929 · Cited by 13
Brief overview of selected approaches in targeting pancreatic adenocarcinoma
Samore, W. R., & Gondi, C. S. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.902933 · Cited by 9
“Utilized in transgenic mouse models, the G12D mutation has been implicated in the pathogenesis of pancreatic intraepithelial neoplasia (PanIN) lesions and the maintenance of PDAC tumors [6].”
BackgroundMalnutrition in Pancreatic Ductal Adenocarcinoma (PDA)
Zolghadri, Y., Choudhuri, S. P., Ocal, O., Layeghi‐Ghalehsoukhteh, S., Berhe, F., Hale, M. A., & Wilkie, T. M. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.11.014 · Cited by 10
Targeting KRAS in pancreatic adenocarcinoma: Progress in demystifying the holy grail
Elhariri, A., Alhaj, A., Ahn, D. H., Sonbol, M. B., Bekaii‐Saab, T., Wu, C., Rutenberg, M. S., Stauffer, J. A., Starr, J. S., Majeed, U., et al. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i8.285 · Cited by 8
Gunda, V., Chhonker, Y. S., Natesh, N. S., Raut, P., Muniyan, S., Wyatt, T. A., Murry, D. J., Batra, S. K., & Rachagani, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112312 · Cited by 8
Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds
Pallara, C., Cabot, D., Rivas, J., Brun, S., Seco, J., Abuasaker, B., Tarragó, T., Jaumot, M., Prades, R., & Agell, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-19703-6 · Cited by 7
“Nonspecific binding was subtracted by using two linked channels (GST-KRAS minus GST).”
MethodPrincipe, D. R., Becker, J. H., Metropulos, A. E., Marinelarena, A. M., Pham, T. D., Aissa, A. F., & Munshi, H. G. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0483 · Cited by 10
ALDH1L2 regulates reactive oxygen species and acinar-to-ductal metaplasia in the pancreas
Hennequart, M., Mervant, L., Stockis, J., Coomes, J., Zarou, M. M., Gerard, L., Tevel, V., Migeot, V., Pilley, S. E., Lee, Y., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01456-5 · Cited by 8
“PanINs then accumulate other oncogenic mutations in genes such as TP53 , CDKN2A and SMAD4 , leading to the development of PDAC over time 2,8,12–14 .”
Moving Towards Dawn: KRas Signaling and Treatment in Pancreatic Ductal Adenocarcinoma
Bhattacharya, S., & Rajpurohit, T. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220128161647 · Cited by 7
Hu, J., Jiang, J., Xu, B., Li, Y., Wang, B., He, S., Ren, X., Shi, B., Zhang, X., Zheng, H., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117590 · Cited by 6
Quémerais, C., Jean, C., Brunel, A., Decaup, E., Labrousse, G., Audureau, H., Raffenne, J., Belhabib, I., Cros, J. F., Perraud, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217538 · Cited by 9
Chen, H., Zu, F., Zeng, T., Chen, Z., Wei, J., Liu, P., Li, Z., Zhou, L., Wang, H., Tan, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.757791 · Cited by 7
Li, X., He, J., & Xie, K. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00664-x · Cited by 7
“For example, co-expression of various digestive enzymes that have not been completely lost in acinar cells and upregulation of duct markers (such as mucin, CK19, SOX9) [18, 76, 77, 181].”
BackgroundTTD consensus document on the diagnosis and management of exocrine pancreatic cancer
Benavides, M., Abad, A., Díaz, I. A., Carrato, A., Díaz‐Rubio, E., Gallego-Plazas, J., García‐Foncillas, J., Grávalos, C., Laquente, B., Pericay, C., et al. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1177-7 · Cited by 6
Sinha, D., Smith, C., & Khanna, R. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.005 · Cited by 7
Ras proteins as therapeutic targets
Chakraborty, A., Linnane, E., & Ross, S. J. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170529 · Cited by 7
Rahal, M., DeWitt, J. M., Patel, H. K., Schmidt, C. M., Ceppa, E. P., Simpson, R. E., Sherman, S., & Al‐Haddad, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07427-6 · Cited by 6
“%) for the diagnosis of MPCs. KRAS and GNAS had sensitivities of 45% (25–56”
InfluentialEmerin is an effector of oncogenic KRAS-driven nuclear dynamics in pancreatic cancer
Flores, L. F., Marks, D. L., Vera, R. E., Sigafoos, A. N., Tolosa, E. J., Almada, L. L., Pease, D. R., Toruner, M. D., Chang, B., Tader, B. R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187799 · Cited by 6
“Mouse cell lines were derived from the genetic crosses described in this manuscript (KC, KPC, KPCE); for complete description of cell line establishment see Collins et al. (38).”
The Hippo signaling pathway modulates pancreatic tissue homeostasis
Wang, X., Du, J., Li, H., Cao, Z., Cheng, Z., & Wang, Z. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02636-0 · Cited by 9
“Oncogenic KRAS mutation, which has been reported as the leading hallmark of PDAC, plays a crucial role in both the initiation and maintenance of PDAC [67].”
McAndrews, K. M., Mahadevan, K. K., Li, B., Comptdaer, A. M., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., et al. (2026) · The EMBO Journal · doi:10.1038/s44318-026-00854-5 · Cited by 12
“…engineered mouse models (GEMMs) have revealed that oncogenic KRAS (KRAS * ) is critical for PDAC initiation and maintenance (Aguirre et al, 2003; Collins et al, 2012; Hingorani et al, 2003; Mahadevan et al, 2023a; Ying et al, 2012), suggesting that targeting KRAS * may provide therapeutic…”
InfluentialModulation of PRC1 Promotes Anticancer Effects in Pancreatic Cancer
Lee, H., Bae, A.-N., Yang, H., Lee, J., & Park, J. H. (2024) · Cancers · doi:10.3390/cancers16193310 · Cited by 7
Ligeiro, D., Rao, M., Maia, A., Castillo-Martín, M., López-Beltrán, A., & Maeurer, M. J. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49270-0_10 · Cited by 5
Tsang, E. S., & Tempero, M. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.22 · Cited by 5
Katsuzaki, Y., Tsukimura, R., Chandela, A., Chano, T., & Ueno, Y. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200125 · Cited by 5
New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting
Heßmann, E., Schneider, G., Bousquet, C., Der, C. J., Dreyer, S. B., Dusetti, N., Eilers, M., Ellenrieder, V., Espinet, E., Falcomatà, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.082 · Cited by 6
Oncogenic KRAS, Mucin 4, and Activin A‐Mediated Fibroblast Activation Cooperate for PanIN Initiation
Hu, C., Huang, C., Hsu, M., Chien, H., Wu, P., Chen, Y., Jeng, Y., Tang, S., Chung, M., Shen, C., et al. (2023) · Advanced Science · doi:10.1002/advs.202301240 · Cited by 7
Hayes, T. K., & Der, C. J. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1806-1_6 · Cited by 9
Immune cells in pancreatic cancer: Joining the dark side
Zhang, Y., McAllister, F. M., & di Magliano, M. P. (2014) · OncoImmunology · doi:10.4161/onci.29125 · Cited by 5
Self-citationThe Increasing Diversity of KRAS Signaling in Pancreatic Cancer
Siveke, J. T. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.026 · Cited by 5
Ward, M. H., Nwosu, Z. C., Poudel, P., Kasperek, S., Tolstyka, Z., Menjivar, R. E., Ragulan, C., Nyamundanda, G., Zhang, L., Andren, A. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.07.447448 · Cited by 9
“Notably, using datasets from our inducible Kras mouse model of PDA (Collins et al., 2012; Ying et al., 2012), we evaluated the Kras-mediated regulation of Upp1.”
MethodKRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer
Wei, Y., Liu, M., Yen, E.-Y., Yao, J., Xun, Z., Nguyen, P. T.-M., Wang, X., Yang, Z., Yousef, A. M. G., Pan, D. N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-2024 · Cited by 7
Fu, J., Ling, J., Li, C.-F., Tsai, C.-L., Yin, W., Hou, J., Chen, P., Cao, Y., Kang, Y., Sun, Y.-C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47242-3 · Cited by 6
“PDAC cells developed the ability to resist anoikis, which is associated with the acquisition of an aggressive tumorigenic and metastatic phenotype in vivo (Collins et al., 2005; Frisch and Francis, 1994).”
The RAS Signaling Network and Cancer
Hibshman, P. S., & Der, C. J. (2024) · Springer eBooks · doi:10.1007/978-3-031-62945-7_17 · Cited by 4
Stromal KITL/SCF Maintains Pancreas Tissue Homeostasis and Restrains Tumor Progression
Oñate, M. K., Oon, C. H., Bhattacharyya, S., Low, V., Chen, C., Zhao, X., Arnold, F., Yan, Z., Pramod, S., Hang, Y., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1079 · Cited by 7
“Acute pancreatitis was induced in male and female mice at 8 weeks of age by intraperitoneal injection of caerulein (80 μg/kg, Sigma-Aldrich, C9026) eight times per day with 1 hour between injections, on two consecutive days, consistent with prior studies (38).”
Cellular Plasticity and Heterogeneity in Pancreatic Regeneration and Malignancy
(2017) · Cancer Cell & Microenvironment · doi:10.14800/ccm.1472 · Cited by 4
Structural basis of the oncogenic KRAS mutant and GJ101 complex
Kim, H. J., Han, C. W., Jeong, M. S., & Jang, S. B. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.12.019 · Cited by 4
Chao, T., Wang, Z., Bowne, W. B., Yudkoff, C. J., Torjani, A., Swaminathan, V., Kavanagh, T. R., Roadarmel, A., Sholevar, C. J., Cannaday, S., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0005-oa · Cited by 4
McAndrews, K. M., Mahadevan, K. K., Li, B., Sockwell, A. M., Morse, S. J., Kelly, P. J., Patel, S. I., Kirtley, M. L., Diaz, B. A. M., Lyu, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635543 · Cited by 4
Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis
Grimont, A., Falvo, D. J., Sisso, W. J., dos Santos, F., Chan, C. W., Zumbo, P., Fall, W. B., Ferrick, K. R., Pan, G., Cleveland, M., et al. (2026) · Developmental Cell · doi:10.1016/j.devcel.2026.06.016 · Cited by 5
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancer
Zhong, Z., Cao, X., Liao, P.-J., Sethi, R., Klomp, J. A., Stalnecker, C. A., Chen, J., Wan, Y., Der, C. J., & Virshup, D. M. (2025) · Journal of Clinical Investigation · doi:10.1172/jci191370 · Cited by 3
Eslinger, C. R., Sonbol, M. B., George, B., Babiker, H., Borad, M. J., & Bekaii‐Saab, T. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s559325 · Cited by 6
“15,16 This temporal primacy under-scores why KRAS has been regarded as the central oncogenic driver of PDAC biology.”
Elhossiny, A. M., Kadiyala, P., Okoye, J. O., Hiraki, H. L., Procario, M. C., Giridharan, T., Watkoske, H. R., Ruckert, M. T., Wang, J., Griffith, B. D., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-2001 · Cited by 9
“Even in models that allow adult activation of oncogenic KRAS (9, 10), expression is driven simultaneously in every epithelial cell of the pancreas, which in turn might cause field effects that are not observed in human spontaneous PanIN.”
Self-citationKRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
Sigafoos, A. N., Tolosa, E. J., Carr, R. M., Fernández‐Barrena, M. G., Almada, L. L., Pease, D. R., Hogenson, T. L., Arul, G. L. R., Mousavi, F., Sen, S., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0464 · Cited by 3
“Authentication of cell lines was done by genotyping as described by Collins and colleagues (24) and by copy-number variation analysis using BioPrime labeling kit (18094011, Invi-trogen).”
A bright future for protein kinase D1 as a drug target to prevent or treat pancreatic cancer
Liou, G., Störz, P., & Leitges, M. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1035477 · Cited by 3
Metadata
- Authors
- Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2012-02-01
- Volume
- 122
- Issue
- 2
- Pages
- 639-653
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3266788
- OpenAlex
- W2018159884
- Cited by
- 770
- References
- 66
- Citations by year
- 2026: 40 · 2025: 41 · 2024: 53 · 2023: 63 · 2022: 71 · 2021: 80 · 2020: 51 · 2019: 43 · 2018: 54 · 2017: 69 · 2016: 56 · 2015: 45 · 2014: 52 · 2013: 41 · 2012: 11
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Association for Cancer Research
- Pancreatic Cancer Action Network
- American College of Surgeons
- Vanderbilt University
- University of Pennsylvania
- University of Michigan
- National Institutes of Health (NIH T32, P30 DK, 5-T32-HD007515)
- National Cancer Institute (R01CA151588, P50CA130810, P50CA13810)
- National Institute of General Medical Sciences (T32GM07315, T32GM007315)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-T32-HD007515, T32HD007505)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, KRAS G12D, oncogenic KRAS, pancreatic carcinogenesis, tumor maintenance, p53, precancerous lesions, epithelial differentiation, Hedgehog signaling, inflammation, tumor microenvironment, tumor regression, KRAS inhibition
- MeSH terms
- Animals, Cell Differentiation, Cell Transformation, Neoplastic, Disease Models, Animal, Epithelial Cells, Humans, Mice, Transgenic, Pancreatic Neoplasms, Pancreatitis, Signal Transduction, Survival Rate, Proto-Oncogene Proteins p21(ras), Mice, Hedgehog Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.